Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.

scientific article published on 29 February 2016

Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/CNCY.21707
P698PubMed publication ID27412420

P50authorMari Mino-KenudsonQ40930518
P2093author name stringEugene J Mark
Mai P Hoang
Michiya Nishino
Vicente Morales-Oyarvide
Tiffany G Huynh
Patricia Della Pelle
P2860cites workAspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinomaQ24650843
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerQ27851588
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaQ27860881
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerQ29620301
p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinomaQ34067972
RET, ROS1 and ALK fusions in lung cancerQ34253845
The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancerQ34262527
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerQ34323659
Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samplesQ34589991
Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classificationQ35875227
Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testingQ37832381
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to EmergeQ41442485
ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterizationQ42435605
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesotheliomaQ43279006
Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung.Q43615551
Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinomaQ44519237
Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organsQ46782763
Rapid multiplex immunohistochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lungQ50279861
Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimensQ50447151
TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks.Q50546790
Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact.Q51368447
Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.Q51624241
Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.Q53244424
Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.Q53582166
Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A.Q54945171
ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material ApproachQ56779202
Immunhistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid Transcription Factor-1, and Vimentin) on Small Biopsies of Non-small Cell Lung Cancer Effectively Parallels the Corresponding Profiling and Eventual DiagQ56779238
A word of caution regarding napsin A expression in squamous cell carcinomas of the lungQ83132058
Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimensQ83240488
Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lungQ83360044
Combined double CK5/P63 stain: useful adjunct test for diagnosing pulmonary squamous cell carcinomaQ83802017
Desmoglein-3 and Napsin A double stain, a useful immunohistochemical marker for differentiation of lung squamous cell carcinoma and adenocarcinoma from other subtypesQ83864179
Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimensQ84390051
Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimensQ84763510
P433issue7
P921main subjectlung carcinomaQ18556110
P304page(s)472-484
P577publication date2016-02-29
P1433published inCancer CytopathologyQ13452937
P1476titleNapsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.
P478volume124

Reverse relations

cites work (P2860)
Q90354850Portrait of Tissue-Specific Coexpression Networks of Noncoding RNAs (miRNA and lncRNA) and mRNAs in Normal Tissues
Q33648661S100A7 promotes lung adenocarcinoma to squamous carcinoma transdifferentiation, and its expression is differentially regulated by the Hippo-YAP pathway in lung cancer cells

Search more.